Pharmaceuticals, Biotechnology and Life Sciences
After receiving and analyzing legally binding transaction offers from two consortia for a public tender offer for all outstanding shares, Stada’s Executive and Supervisory Board has reached the conclusion to support the bid by Bain Capital and Cinven.
The Executive Board of Stada Arzneimittel AG has published the final figures for financial year 2016 which are, due to the revaluation of a transaction, diferent from the preliminary figures which the company had already published on March 1, 2017.
Stada’s Supervisory Board has postponed expert sessions which were planned as part of the structured bidding process.
On Thursday, STADA Arzneimittel AG confirmed that it has received another legally non-binding conditional expression of interest regarding a bid for the acquisition of up to 100 percent of the shares in the company at an indicative takeover price of €58.00 per share.
As German generics drugmaker Stada confirmed receiving offers to be bought out, it has simultaneously made a deal with a Sweden-based life science company Enzymatica, to sell its common cold mouth spray ColdZyme in Germany.
German drugmaker Stada has confirmed certain rumours about receiving takeover offers from a private equity firm, Cinven Partners and one other unnamed bidder.
Futura Medical (Futura) has signed a licensing agreement with the UK subsidiary of STADA Arzneimittel AG (STADA), for the commercialisation of TPR100, its pain relief gel.
Stada reports financial results for Q3 2016…